XML 35 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Dispositions of Real Estate and Discontinued Operations
3 Months Ended
Mar. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Dispositions of Real Estate and Discontinued Operations Dispositions of Real Estate and Discontinued Operations
2023 Dispositions of Real Estate
In January 2023, the Company sold two life science facilities in Durham, North Carolina, which were classified as held for sale as of December 31, 2022, for $113 million, resulting in total gain on sales of $60 million. Additionally, in March 2023, the Company sold two MOBs for $32 million, resulting in total gain on sales of $21 million.
2022 Dispositions of Real Estate
During the three months ended March 31, 2022, the Company sold one life science facility in Salt Lake City, Utah for $14 million, resulting in a gain on sale of $4 million.
During the three months ended June 30, 2022, the Company sold three MOBs and one MOB land parcel for $27 million, resulting in total gain on sales of $10 million.
During the three months ended September 30, 2022, the Company sold two MOBs for $9 million, resulting in total gain on sales of $1 million.
Held for Sale and Discontinued Operations
In 2020, the Company concluded that the dispositions of its senior housing triple-net and SHOP portfolios represented a strategic shift that had a major effect on its operations and financial results. Therefore, senior housing triple-net and SHOP assets are classified as discontinued operations in all periods presented herein.
At each of March 31, 2023 and December 31, 2022, the total assets and total liabilities classified as discontinued operations were zero.
As of March 31, 2023, no assets were classified as held for sale. As of December 31, 2022, two life science assets were classified as held for sale, with an aggregate carrying value of $50 million, primarily comprised of net real estate assets of $44 million. As of December 31, 2022, liabilities related to these assets held for sale were $4 million. These two life science assets were sold in January 2023, as discussed above.
The results of discontinued operations during the three months ended March 31, 2023 and 2022 are presented below (in thousands) and are included in the consolidated results of operations for the three months ended March 31, 2023 and 2022:
Three Months Ended
March 31,
20232022
Revenues:
Resident fees and services$— $2,655 
Total revenues— 2,655 
Costs and expenses:
Operating— 2,674 
Total costs and expenses— 2,674 
Other income (expense):
Gain (loss) on sales of real estate, net— (71)
Other income (expense), net— 
Total other income (expense), net— (68)
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures— (87)
Income tax benefit (expense)— 340 
Equity income (loss) from unconsolidated joint ventures— 64 
Income (loss) from discontinued operations$— $317 
Impairments of Real Estate
During the three months ended March 31, 2023 and 2022, the Company did not recognize any impairment charges.
Other Losses
During the three months ended March 31, 2022, the Company recognized $14 million of expenses within other income (expense), net on the Consolidated Statements of Operations for tenant relocation and other costs associated with the demolition of an MOB.